Human regulatory T cells suppress proliferation of B lymphoma cells

References

• Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167–1174.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–2964.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193–200.
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 2009;94:70–77.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637–650.
   PubMed Web of Science ®Google Scholar
• Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49:247–256.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 + regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958–965.
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25:390–398.
   PubMed Web of Science ®Google Scholar
• Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27:31–39.
   PubMed Web of Science ®Google Scholar
• Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115:289–295.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4 + CD25 + regulatory T-cell-mediated suppression of infiltrating CD4 + T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639–3646.
   PubMed Web of Science ®Google Scholar
• Glowala-Kosinska M, Chwieduk A, Nieckula J, et al. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol. 2013;91:122–128.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20:677–682.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Escriva P, et al. Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit Rev Oncol Hematol. 2009;70:103–113.
   PubMed Web of Science ®Google Scholar
• Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest. 2004;114:1640–1649.
   PubMed Web of Science ®Google Scholar
• Lim HW, Hillsamer P, Banham AH, et al. Cutting edge: direct suppression of B cells by CD4 + CD25 + regulatory T cells. J Immunol. 2005;175:4180–4183.
   PubMed Web of Science ®Google Scholar
• Zhao DM, Thornton AM, Di Paolo RJ, et al. Activated CD4 + CD25 + T cells selectively kill B lymphocytes. Blood. 2006;107:3925–3932.
   PubMed Web of Science ®Google Scholar
• Lindqvist CA, Christiansson LH, Thorn I, et al. Both CD4 + FoxP3 + and CD4 + FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 2011;133:296–306.
   PubMed Web of Science ®Google Scholar
• Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499.
   PubMed Web of Science ®Google Scholar
• Trzonkowski P, Bieniaszewska M, Juscinska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol. 2009;133:22–26.
   PubMed Web of Science ®Google Scholar
• DiIanni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921–3928.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061–1070.
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. Suppressor effector function of CD4 + CD25 + immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–190.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood. 2005;105:4743–4748.
   PubMed Web of Science ®Google Scholar
• Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 2009;69:599–608.
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–1711.
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203:1693–1700.
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4 + T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911.
   PubMed Web of Science ®Google Scholar
• Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589–601.
   PubMed Web of Science ®Google Scholar
• Grossman WJ, Verbsky JW, Tollefsen BL, et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 2004;104:2840–2848.
   PubMed Web of Science ®Google Scholar
• Woroniecka R, Rymkiewicz G, Grygalewicz B, et al. Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of CD52, CD62L and increase of CD71 antigen expression as the most frequent recurrent abnormalities. Am J Clin Pathol. 2015;143:25–35.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Larsen JK, Christiansen J, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood. 2000;96:2219–2225.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res. 2004;10:8309–8317.
   PubMed Web of Science ®Google Scholar
• Travert M, Ame-Thomas P, Pangault C, et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008;181:1001–1011.
   PubMed Web of Science ®Google Scholar
• Ito D, Frantz AM, Williams C, et al. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma. 2012;53:1390–1398.
   PubMed Web of Science ®Google Scholar
• Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+ Foxp3+ cells. J Exp Med. 2008;205:565–574.
   PubMed Web of Science ®Google Scholar
• Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA. 2008;105:7797–7802.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Boeld TJ, Eder R, et al. Loss of FOXP3 expression in natural human CD4 + CD25 + regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol. 2009;39:1088–1097.
   PubMed Web of Science ®Google Scholar
• Gabrysova L, Christensen JR, Wu X, et al. Integrated T-cell receptor and costimulatory signals determine TGF-beta-dependent differentiation and maintenance of Foxp3 + regulatory T cells. Eur J Immunol. 2011;41:1242–1248.
   PubMed Web of Science ®Google Scholar
• Marek N, Bieniaszewska M, Krzystyniak A, et al. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant. 2011;20:1747–1758.
   PubMed Web of Science ®Google Scholar
• Tresoldi E, Dell'Albani I, Stabilini A, et al. Stability of human rapamycin-expanded CD4 + CD25 + T regulatory cells. Haematologica. 2011;96:1357–1365.
   PubMed Web of Science ®Google Scholar
• Valmori D, Tosello V, Souleimanian NE, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4 + T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4 + T cells. J Immunol. 2006;177:944–949.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Baker J, Leveson-Gower DB, et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4 + CD25 + Foxp3 + regulatory T cells. Blood. 2011;118:2342–2350.
   PubMed Web of Science ®Google Scholar
• Toker A, Engelbert D, Garg G, et al. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol. 2013;190:3180–3188.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Josefowicz S, Chaudhry A, et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010;463:808–812.
   PubMed Web of Science ®Google Scholar
• Polansky JK, Schreiber L, Thelemann C, et al. Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl). 2010;88:1029–1040.
   PubMed Web of Science ®Google Scholar
• Feng Y, Arvey A, Chinen T, et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell. 2014;158:749–763.
   PubMed Web of Science ®Google Scholar
• Hansmann L, Schmidl C, Kett J, et al. Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. J Immunol. 2012;188:1275–1282.
   PubMed Web of Science ®Google Scholar
• Schmidl C, Hansmann L, Andreesen R, et al. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. Eur J Immunol. 2011;41:1491–1498.
   PubMed Web of Science ®Google Scholar
• Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000–1007.
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Deknuydt F, Raimbaud I, et al. Human memory FOXP3 + Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma.t. Proc Natl Acad Sci USA. 2009;106:8635–8640.
   PubMed Web of Science ®Google Scholar
• Valmori D, Raffin C, Raimbaud I, et al. **Human RORγt + TH17 cells preferentially differentiate from naive FOXP3 + Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci USA. 2010;107:19402–19407.
   PubMed Web of Science ®Google Scholar
• Beriou G, Costantino CM, Ashley CW, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood. 2009;113:4240–4249.
   PubMed Web of Science ®Google Scholar
• Rubtsov YP, Niec RE, Josefowicz S, et al. Stability of the regulatory T cell lineage in vivo. Science. 2010;329:1667–1671.
   PubMed Web of Science ®Google Scholar
• Gao Y, Lin F, Su J, et al. Molecular mechanisms underlying the regulation and functional plasticity of FOXP3(+) regulatory T cells. Genes Immun. 2012;13:1–13.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Vignali DA, Rudensky AY, et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13:461–467.
   PubMed Web of Science ®Google Scholar
• Fu W, Ergun A, Lu T, et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol. 2012;13:972–980.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Rudra D, Treuting P, et al. CD4 + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009;326:986–991.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–356.
   PubMed Web of Science ®Google Scholar
• Koch MA, Tucker-Heard G, Perdue NR, et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595–602.
   PubMed Web of Science ®Google Scholar
• Wang Y, Souabni A, Flavell RA, et al. An intrinsic mechanism predisposes Foxp3-expressing regulatory T cells to Th2 conversion in vivo. J Immunol. 2010;185:5983–5992.
   PubMed Web of Science ®Google Scholar
• Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35:337–348.
   PubMed Web of Science ®Google Scholar
• Yu F, Sharma S, Edwards J, et al. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat Immunol. 2015;16:197–206.
   PubMed Web of Science ®Google Scholar
• Dong S, Maiella S, Xhaard A, et al. Multiparameter single-cell profiling of human CD4 + FOXP3 + regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood. 2013;122:1802–1812.
   PubMed Web of Science ®Google Scholar
• d'Hennezel E, Yurchenko E, Sgouroudis E, et al. Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3 + cells. J Immunol. 2011;186:6788–6797.
   PubMed Web of Science ®Google Scholar
• Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3 + regulatory T cells in human thymus and periphery. Immunity. 2008;28:870–880.
   PubMed Web of Science ®Google Scholar
• Husson H, Freedman AS, Cardoso AA, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol. 2002;119:492–495.
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang X, Medeiros LJ, et al. Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol. 2003;201:404–412.
   PubMed Web of Science ®Google Scholar
• Machado L, Jarrett R, Morgan S, et al. Expression and function of T cell homing molecules in Hodgkin's lymphoma. Cancer Immunol Immunother. 2009;58:85–94.
   PubMed Web of Science ®Google Scholar
• van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol. 1999;154:1685–1691.
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood. 1999;93:2463–2470.
   PubMed Web of Science ®Google Scholar
• Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer. 2003;107:197–201.
   PubMed Web of Science ®Google Scholar
• Buri C, Korner M, Scharli P, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood. 2001;97:1543–1548.
   PubMed Web of Science ®Google Scholar
• Hedvat CV, Jaffe ES, Qin J, et al. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol. 2001;14:1270–1276.
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L + T cells by producing CCL22. Eur J Immunol. 2002;32:1403–1413.
   PubMed Web of Science ®Google Scholar
• Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110:3316–3325.
   PubMed Web of Science ®Google Scholar
• Ek S, Bjorck E, Hogerkorp CM, et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 2006;118:2092–2097.
   PubMed Web of Science ®Google Scholar
• Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L + subpopulation of CD4 + CD25 + regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220–2226.
   PubMed Web of Science ®Google Scholar
• Sage PT, Francisco LM, Carman CV, et al. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol. 2013;14:152–161.
   PubMed Web of Science ®Google Scholar
• Dakappagari N, Ho SN, Gascoyne RD, et al. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry B Clin Cytom. 2012;82:112–119.
   PubMed Web of Science ®Google Scholar
• Saze Z, Schuler PJ, Hong CS, et al. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood. 2013;122:9–18.
   PubMed Web of Science ®Google Scholar
• Kobata T, Jacquot S, Kozlowski S, et al. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA. 1995;92:11249–11253.
   PubMed Web of Science ®Google Scholar
• Wing JB, Sakaguchi S. Foxp3(+) T(reg) cells in humoral immunity. Int Immunol. 2014;26:61–69.
   PubMed Web of Science ®Google Scholar
• Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119:2844–2853.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Kanno Y, Tanaka Y, et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol. 2000;164:4097–4104.
   PubMed Web of Science ®Google Scholar
• Epron G, Ame-Thomas P, Le Priol J, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2012;26:139–148.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713–4720.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120:1412–1421.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220–3224.
   PubMed Web of Science ®Google Scholar
• Myklebust JH, Irish JM, Brody J, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013;121:1367–1376.
   PubMed Web of Science ®Google Scholar
• Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655–2661.
   PubMed Web of Science ®Google Scholar
• Reichardt W, Durr C, von Elverfeldt D, et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol. 2008;181:4770–4779.
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. Tcell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113:3546–3552.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–399.
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, et al. CD4 + CD25 + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–1150.
   PubMed Web of Science ®Google Scholar